Please login to the form below

myelofibrosis

This page shows the latest myelofibrosis news and features for those working in and with pharma, biotech and healthcare.

France’s Innate Pharma eyes $100m Nasdaq IPO

That includes continuing clinical development of anti-KIR3DL2 antibody IPH4102 for the treatment of patients with Sézary syndrome – a form of cutaneous T cell lymphoma (CTCL) – as well as myelofibrosis and

Latest news

BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

Currently in the middle of merger. After a turbulent development, Celgene has finally claimed FDA approval for Inrebic, its new drug for rare bone marrow disorder myelofibrosis. ... That deal is worth up to $7bn but is weighted to fedratinib’s
Triplet approvals for myeloma boost Celgene in Q2

Also nearing the market are fedratinib for myelofibrosis which could be approved in September, luspatercept for myelodysplastic syndromes – with an FDA decision due next April – and ozanimod for multiple sclerosis, which
Celgene files luspatercept ahead of key merger vote

It is also being studied in the BEYOND phase 2 trial in non-transfusion-dependent beta-thalassemia, and a phase 2 trial in myelofibrosis.
Celgene to launch five new products through to 2020

myelofibrosis, thalassaemia therapy luspatercept, and CAR-T candidates lisocabtagene maraleucel (liso-cel) for lymphoma and bb2121 for multiple myeloma.
Geron poleaxed as partner J&J abandons only pipeline drug

of imetelstat in relapsed/refractory myelofibrosis (MF).

More from news
Approximately 8 fully matching, plus 38 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

The headline value contains significant sales milestones linked to performance of Impact's lead phase III stage asset fedratinib, an oral JAK2 kinase inhibitor in development for the treatment of myelofibrosis ... Acquisition company - remaining 90%. 9
Pharma deals in August 2015

Acquisition ‐ company. 1300. Promedior. BMS. PRM 151 recombinant pentraxin‐2 protein for idiopathic pulmonary fibrosis and myelofibrosis.
Pharma deals during November 2014

Good news at last. Days after finally getting the FDA's go-ahead to resume development of its lead candidate, imetelsta, for myelofibrosis and myelodysplastic syndrome, Geron has signed a deal
NICE and ‘ultra orphans’

It won't, for example, affect medicines such as Novartis' treatment for myelofibrosis, a rare blood cancer of which there are only around 0.4 cases of the condition per 100,
Pharma deals during November 2013

patients with myelofibrosis and has activity against genetic mutations linked to myelofibrosis, leukaemia and certain solid tumours.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

Boston Biomedical appoints commercial head

At Incyte, she established the company's commercial operations and successfully launched Jakafi (ruxolitinib) for myelofibrosis as part of a collaboration with Novartis.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

THE OTHER SIDE OF...BLOOD CANCER

Meet Sophie. What she suffers from you have probably never heard of: a blood cancer, or neoplasm, called myelofibrosis.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director, Medical Education: Salary TBC

Editorial Assistants - Medical Communications agency - Cheshire: Excellent Remuneration Package

Experienced / Senior Medical Writer - Excellent Progression Oppo...: Excellent Salary and Benefits on offer

Senior Copywriter: Salary TBC

Senior Medical Writer: Salary TBC

Senior Account Manager / Account Director - MedComms - London: Highly competitive salary &package

Senior Medical Writer – Medical Communications – North West – In...: Excellent Remuneration Package

Senior / Principal Medical Writers wanted - MedComms - Various U...: Excellent Remuneration Packages

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Subscribe to our email news alerts

PMHub

Add my company

Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...